272
e,ns
ltaoeBmo
o
s
evNNYivrulsareeecs
rstfieo
s
s
-VmeeNYYnoisses
rs
s
eegtchhoessrdetataA
pifo o SfeHNHSFP),yelshntenospooA
sDmg
e(m5522NrlaiS
trF5
.aP224
4pRe
Ps,nestoaspeesR
R
D
sBeirPPSdne
onisit
sd
h
tsLr134ergy
orppareDtPnht,aoervsoumaijeero
sPdhA
acNA
NidetlnbaavtrsouijrT
DPdaHA
s
eoNYNS,ba7
6miuKA
A
ANNNzutse
as
vruittiRtaAsAHPtsNoPN,dese
e
a2vveiibRs
vutt-aaiteEtiaggsnHteeoasNNPxate
e
e
s
vvvTuiii,tttRtiiidassseEtooossPPPab-s
eitnasilloancieytggcianaatiA
B
IsdNIVrIIhtneadaAr,GA
t2
1
Nney
mtgaoelrottlsaiHA
C
AnNDINomre
oghA9
9
2764Td
He,u,en]ls
i5.bet1lsaan[nastlao.itleocayaszavatat1e2
aeBbu-eltaanee
anomlH´g rnbmweid]
o]
atnsaa4m6taarlop1r1AeTNgAeR[a[dCNM123
BreastCancerResTreat(2015)149:269–275
37.5%,III43.8%,IV6.2%.52.9%ofpatientshadagrade3carcinoma,followedbygrade2(35.3%)andgrade1(11.8%).ERwaspositiveinalleligiblecases,PRwaspositiveinthevastmajorityofpatients(93.3%),whereaski-67wasreportedonlyinthestudybyZagourietal.[9].HER2wasnegativeinthemajorityofpatients(82.6%).Adjuvanthormonaltreatmentwasadministeredin87.5%ofcaseswherethisinformationwasprovided(n=16);ofnotein7/23casestherelevantdatawerenotreported.Regardingpreviouslygivenadjuvantchemotherapy,56.25%ofpatientshadreceivedanthracyclineandtaxane-basedchemotherapy,25%hadreceivedanthracyclinealone,6.25%taxanealone,whereas12.5%hadnotreceivedadjuvantchemotherapy;trastuzumabwasco-administeredinonepatientintheadjuvantsetting.
Fulvestrantwasgivenas rstorsecondlinein40%ofpatients,whileasthirdlineorbeyondin60%ofpatients.Inallcaseswherefulvestrantdosewasrepor-ted,itwasequalto250mgmonthlywithloadingdose500mg;ofnote,inonecase[16]fulvestrantwascom-binedwithtrastuzumabadministration(trastuzumabbeyondprogression).79.0%ofpatientsatfulvestrantadministrationhadvisceralmetastases;whereas66.7%ofmalebreastcancerpatientssufferedfrombonemetastases.Regardingbestresponse,in26.1%PRwasachieved,in47.8%ofcasesSDwasrecorded,whereasin26.1%ofpatientsPDwasnoted.ThemedianPFSwasequalto5months.Kaplan–Meiersurvivalestimateregardingprogression-freesurvivalisdepictedinFig.2.Regardingadverseevents,nograde3and4eventswererecorded;ofnote,hot asheswerereportedin18.2%ofmalebreastcancerpatients.
LackofreporteddatawasobservedregardingOSinthemajorityofeligiblestudies;therefore,nopoolingwasundertakeninviewofthedatascarcity.Speci cally,OSwasnotreportedinthestudiesbyAgrawaletal.[15],Carmona-Bayona[16],delaHambaetal.[14],aswellasinfouroutof vepatientsincludedinthestudybyMascietal.[13];notably,the fthpatientinthelatterstudy[13]didnotdiefrombreastcancer.
Table2presentstheresultsofunivariateCoxregressionandunivariatelogisticregressionanalysesregardingPFSandclinicalbene t,respectively.Noassociationswithageatfulvestrantadministration,linesoftreatment,grade,initialstageatdiagnosis,HER2status,PRstatus,adjuvanthormonaltreatment,adjuvantchemotherapy,visceralmetastases,bonemetastases,hot asheswerenoted.InadditiontotheassociationspresentedinTable2,itseemsinterestingtonotethattheoccurrenceofhot ashesdidnotcorrelatewithage(p=0.294,Fisher’sexacttest)despiteanumerictrend(11.1%ofpatientsolderthanthemedianexperiencedhot ashesversuss37.5%ofpatientsyoungerthanthemedian).
(×200)?From?Zagouri?et? al?BMC?Cancer?2010 Hsp90?Expression?in?Breast?Cancers?by?protein? expression?analysis?(AQUA)?From?Pick?et?al?Cancer? ...
Greece? (Zagouri? F);? and? Department?of?Surgery,?Red?Cross?Hospital,?Athens,?Greece?(Karaliotas?K) Corresponding? Author:? Flora? Zagouri,? MD,? ...
A Case Study of an in Situ Botanical Garden in Zagori, Greece_电子/电路_工程科技_专业资料。Journal ofAgricultural Science and Technology B 3(2 ...
热门文档